Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

Jan Albert Kuivenhoven, Greetje J. de Grooth, Hitoshi Kawamura, Anke H. Klerkx, Francois Wilhelm, Mieke D. Trip, John J.P. Kastelein

Research output: Contribution to journalArticleAcademicpeer-review

175 Citations (Scopus)


The inhibition of cholesteryl ester transfer protein (CETP) has recently been shown to effectively increase high-density lipoprotein (HDL) cholesterol. This study examined the use of the CETP inhibitor JTT-705 combined with pravastatin. In a randomized, double-blind, placebo-controlled trial, 155 patients with type II dyslipidemia using pravastatin 40 mg were treated with placebo or JTT-705 300 or 600 mg. Four weeks of treatment with JTT-705 600 mg led to a 30% decrease in CETP activity (p <0.001), a 28% increase in HDL cholesterol (p <0.001), and a 5% decrease in low-density lipoprotein cholesterol (p <0.03). Combination therapy using JTT-705 and pravastatin effectively increases HDL cholesterol levels and is safe and well tolerated up to 4 weeks of administration.

Original languageEnglish
Pages (from-to)1085-1088
Number of pages4
JournalAmerican Journal of Cardiology
Issue number9
Publication statusPublished - 1-May-2005
Externally publishedYes


  • Carrier Proteins
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Glycoproteins
  • Humans
  • Hyperlipidemias
  • Hypolipidemic Agents
  • Male
  • Middle Aged
  • Placebos
  • Pravastatin
  • Sulfhydryl Compounds
  • Treatment Outcome

Cite this